S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

$12.01
+1.02 (+9.28 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$10.80
Now: $12.01
$12.55
50-Day Range
$9.25
MA: $10.66
$12.11
52-Week Range
$7.43
Now: $12.01
$21.19
Volume810,744 shs
Average Volume407,324 shs
Market Capitalization$587.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.12 million
Book Value$5.75 per share

Profitability

Net Income$-171,450,000.00
Net Margins-303.08%

Miscellaneous

Employees364
Market Cap$587.99 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) announced its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The biopharmaceutical company earned $25.19 million during the quarter, compared to analysts' expectations of $10.74 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. View MacroGenics' Earnings History.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for MacroGenics.

What price target have analysts set for MGNX?

11 brokers have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $21.20 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for MacroGenics.

What is the consensus analysts' recommendation for MacroGenics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:
  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (2/20/2020)
  • 2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019)

Has MacroGenics been receiving favorable news coverage?

News coverage about MGNX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for MacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,180,000 shares, an increase of 14.5% from the January 15th total of 3,650,000 shares. Based on an average daily volume of 575,700 shares, the days-to-cover ratio is presently 7.3 days. Approximately 9.5% of the company's stock are short sold. View MacroGenics' Current Options Chain.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 67)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.94%), Sofinnova Investments Inc. (2.40%), Rhenman & Partners Asset Management AB (2.17%), Pinnacle Associates Ltd. (1.75%), FMR LLC (1.70%) and Candriam Luxembourg S.C.A. (1.53%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

Which institutional investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Jefferies Group LLC, Spark Investment Management LLC, Massachusetts Financial Services Co. MA, Citigroup Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for MacroGenics.

Which institutional investors are buying MacroGenics stock?

MGNX stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Panagora Asset Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Principal Financial Group Inc. and Amia Capital LLP. View Insider Buying and Selling for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $12.01.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $587.99 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

What is MacroGenics' official website?

The official website for MacroGenics is http://www.macrogenics.com/.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  685
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel